Board of Directors

R. Douglas Kahn, MBA

Chairman, CEO & President

Doug is a technology executive and entrepreneur with 30 years experience ranging from start-ups to large publicly traded companies.  He served as Chairman and CEO of Ahura Scientific Corporation from 2003-2010.  There he guided this manufacturer of handheld spectroscopic instruments from start-up to sale.  The company was acquired by Thermo Fisher Scientific for approximately $190M. Prior to this, he was CEO of PanAmSat, the world’s largest public satellite services company with annual revenues in excess of $800 million. Previously, he served as President and CEO of Easel Corporation, taking it from its early stage venture capital days through a successful IPO and four years beyond.  Doug holds a BS in Engineering from Cornell University and an MBA from Stanford University.  Doug currently serves as a Trustee of Olin College of Engineering, Needham, MA where he is also Chairman of the Investment Committee.   He was a past recipient of the Entrepreneur of the Year award and the SBANE New Englander award for innovation and achievement. He served previously as Director of Advanced Visual Systems, ServiceSoft Corp, Rosh Intelligent Systems and others.

Theodore Clark, PhD

Director & Chief Scientific Officer

Ted Clark

Ted is the company founder and a Professor in the Department of Microbiology and Immunology at Cornell University. He has more than 20 years experience in cell and molecular biology, and has worked extensively with Tetrahymena and other ciliates. Ted received his PhD in Cell and Developmental Biology from the State University of New York at Stony Brook and did his postdoctoral training at Yale University. He spent more than a decade at the University of Georgia where he began efforts to develop Tetrahymena as an alternative expression host for recombinant proteins. He is Director of the Graduate Program in Immunology at Cornell and is a member of the board of reviewers for the Journal of Eukaryotic Microbiology.

Marc R. Cote

Representing Boston Harbor Angels

Marc Cote

Marc is a co-founder, partner and the Chief Operating Officer of Accellient Partners, a drug development and biotech start-up firm.  He is also a co-founder and COO of Ternus Pharma, a development stage biotech developing a new improved general anesthetic.  He also co-founded Synchroneuron Inc., a clinical stage CNS focused biotech, and was the CFO/COO where he led the company through both its Series A and B venture rounds.  Marc spent over ten years at Dunkin’ Brands where he was Vice President of Finance and Shared Services and he started his career in the Entrepreneurial Services Group at Ernst & Young.  Marc is a member of Boston Harbor Angels where he is an active investor.  In addition, he is a Co-Chair of Mass Bio’s Entrepreneur University.  Marc is a graduate of Bentley College, summa cum laude.

Martin Gorovsky, PhD

Director

Martin Gorovsky

Marty is the Rush Rhees Professor Emeritus of Biology at the University of Rochester. He received his PhD from the University of Chicago and his postdoctoral training at Yale University. His laboratory played a major role in developing molecular genetic techniques that led to the decision by the NIH and NSF to sequence the genome of Tetrahymena thermophila as a model for research in cell biology and genetics. His work was cited as one of the major contributions to Science Magazine’s election of RNAi as “Breakthrough of the Year” in 2002. He received the University of Rochester Cancer Center Davey Memorial Award for outstanding cancer research. He is the founder of graduate courses that have become mainstays of programs for graduate students in both the Medical School and the Biology Department.

Christopher Taron, PhD

Director

Chris Taron

Chris is Head of the Gene Expression Division at New England Biolabs (NEB), a world leader in recombinant enzyme production. He received his PhD from the University of Illinois, Urbana and was a Co-founder and Director at BioDisplay Technologies Inc., prior to its acquisition by Abbott Laboratories. He played a leading role in the commercial development of the K. lactis yeast-based protein expression platform sold in NEB’s catalog and used for internal manufacturing. As head of NEB’s Gene Expression Division, he oversees the development of novel technologies that improve protein production in microbes. Additionally, his research lab is focused on glycobiology with an interest in the biosynthesis of various types of protein glycosylation.

Robert Gailus, MBA

Director

Robert Gailus

Bob is an experienced venture investor and advisor. He was a founding member of Schroder Ventures/U.S., the venture affiliate of Schroders, the London merchant bank. Bob has invested in more than 75 early-stage companies, including Celgene, Cell Therapeutics, Incyte Pharmaceuticals, and Neurogen. He founded Software Technology Venture Partners (“STVP”) in NYC, New York to invest in and advise IT companies in the Boston to NYC corridor. He joined with Bob Levenson, a successful entrepreneur and Fortune 500 operating executive (ADP, Medco and First Data Corp.), and formed LENOX Capital Group, LLC, to invest in early-stage technology and service companies. Bob is a former member of the New York Angels, and has been the Venture Advisor to OgdenCAP in New York City since 2007. Bob holds a BA from Columbia College (Academic All-American) and an MBA from Columbia University.

Peter Kiener, PhD

Director

Peter Kiener

Peter is currently the Chief Scientific Officer and Head of R&D at Sucampo Pharma Americas LLC. Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates. From 2009 to 2013, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener previously worked on biologics for Bristol-Myers Squibb from 1983 to 2001.